Hansa Biopharma — Juli 2022

[rolling]

Enig med jer begge. Det er et super stof hansa har udviklet..Mange muligheder i mange indikationer

[exitnu]

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform

https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2022/Hansa-Biopharma-announces-70-million-non-dilutive-product-finance-transaction-with-NovaQuest-to-support-continued-development-of-the-companys-antibody-cleaving-enzyme-technology-platform/default.aspx

[exitnu]

"Proceeds will be mainly utilized to:

Further strengthen the Company’s position in kidney transplantation through the continued support of ongoing European commercial launch activities for Idefirix (imlifidase) and execution of the U.S. ConfIdeS trial of imlifidase, which is expected to support a potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway in the first half of 2024. In addition, Hansa will advanc

[exitnu]

.... In addition, Hansa will advance the global Phase 3 clinical trial of imlifidase in anti-GBM antibody disease and ongoing clinical programs in other indications"

[Helge_LarsenPI-redaktør]

Fra debatteb: https://www.proinvestor.com/boards/104550/

[exitnu]

Hansa Biopharma AB: Hansa Biopharma half year report 2022

Hansa Biopharma half year report 2022

•    Continued solid sales in Q2 •    Positive NICE recommendation obtained  •    Completed

News Powered by Cision (news.cision.com)

[exitnu]

TUE, JUL 19, 2022 08:00

• Continued solid sales in Q2

• Positive NICE recommendation obtained

• Completed enrollment in imlifidase Phase 2 program in AMR

• Peter Nicklin elected as new Chairman of the Board of Directors

[Jazzz]

Gode meldinger over hele linien. Voldsomt spændende aktie med en meget rimelig risk-benefit. Ikke så tit man finder dem.

[exitnu]

"Start of Volatility Halt Auction Period: Order book 'HNSA' in market 'STO Equities CCP' at 10:06:11.879"

[exitnu]

Tilsyneladende har markedet taget ret positivt imod halvårsrapporten

[Stroka]

Jeg sidder med et mega papirtab i aktien. Har været lige ved at tage tabet mange gang siden nedturen for alvor startede. Det gør jeg så ikke nu.

[exitnu]

Husk CC idag kl. 14:00.

The webcast will be available on:

Page Not Found - streams.eventcdn.net

(streams.eventcdn.net)

[exitnu]

Pænt luk i kurs 79 med stor volumen. 40,95%.

En god dag på kontoret

[Stroka]

• 40.96% i dag. Det må være bundvendingen vi har set i dag.

[exitnu]

... +40,95%.

[Stroka]

[exitnu]

Hansa Biopharma Q2; Idefirix sales progress and secured funding to end 2024

Just a moment...

(www.redeye.se)

[exitnu]

Hansa Biopharma AB (publ) (HNSBF) CEO Søren Tulstrup on Q2 2022 Results - Earnings Call Transcript

Access to this page has been denied

px-captcha

(seekingalpha.com)

[B.Andersen]

SEB:
Lift target price to SEK 260 (230)
We raise our Idefirix estimates on the back of the sales beat, and update ourmodel to reflect the financing from NovaQuest. Accordingly, we raise our SOTP-rNPV-based target price to SEK 260 (230) and reiterate our Buy rating".

[B.Andersen]

CARNEGIE OPJUSTER KURSMÅL TIL SEK 121.

ERIK PENSER BANK TIL SEK 240-250

RBC TIL SEK 171